They aimed either to limit the initial SIRS (and thus the CARS) in particular by the use of low-dose glucocorticoids [3, 12] or to restore the secretion of pro-inflammatory cytokines by the use of IFN-γ, GM-CSF [26], or interleukin 12 [27]. This evidence concerns the gene CSF2 and systemic inflammatory response syndrome.